Mankind Pharma Limited (MANKIND.BO) Seasonal returns chart
NiveshIQ
NSE: MANKIND · Healthcare
Mankind Pharma Ltd.
₹2,481.20▼ ₹11.60 (-0.47%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on MANKIND. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Mankind Pharma Ltd.
Mankind Pharma Limited is a diversified Indian healthcare company that develops, manufactures, and markets pharmaceutical formulations and consumer health products across acute and chronic therapeutic segments, including anti‑infective, cardiovascular, gastrointestinal, and dermatology. In FY27, the company reported revenue of ₹14,738 crore and net income of ₹2,043 crore, driven by a 17% revenue rise to ₹4,433 crore in Q2 FY27 and a 39% profit jump to ₹712 crore. The growth was largely supported by increased demand for chronic disease therapies, which expanded margins and contributed to a 39% rise in Q2 earnings. Mankind Pharma also maintains a consumer healthcare portfolio featuring condoms, pregnancy detection kits, and vitamin supplements, adding diversification to its revenue mix. The
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹10,335 Cr +18.12% | ₹12,207 Cr +18.12% | ₹14,278 Cr +16.96% |
| EBITDA Margin | 24.53% | 24.72% | 25.34% |
| Net Profit | ₹1,913 Cr +49.23% | ₹1,986 Cr +3.84% | ₹1,913 Cr -3.70% |
| EPS | ₹47.75 | ₹49.28 | ₹46.35 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Mankind Pharma Limited (MANKIND.BO) Seasonal returns chart
MANKIND PHARMA LIMITED Option Chain - Live MANKIND PHARMA LIMITED Option Chain Data, OI & Price
🔒
+ 3 more stories about Mankind Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹4, 338 Cr, PAT ₹711 Cr, EPS ₹17.23, EBITDA margin 27.0%. Growth context: revenue YoY +17.3%, PAT YoY +39.1%, revenue QoQ +7.6%, PAT QoQ +23.9%.
Management highlights product launches, approvals, and therapy‑mix improvement as the main near‑term growth drivers, wit...
FY26 (last completed FY): revenue ₹14, 278 Cr, PAT ₹1, 913 Cr, EBITDA margin 25.3%, EPS ₹46.35. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for MANKIND
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track MANKIND alongside your other holdings
Unlock full MANKIND research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Mankind Pharma Ltd.?
NiveshIQ detects active intelligence signals for Mankind Pharma Ltd. (MANKIND) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Mankind Pharma Ltd.?
Mankind Pharma Ltd. operates in the Healthcare sector with a market capitalisation of ₹10,002,830.5L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.